Related Experiment Video

Updated: Oct 2, 2025

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device
09:36

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device

Published on: September 24, 2020

2.9K

Multi-drug Treatment for COVID-19-induced Acute Respiratory Distress Syndrome

Masashi Ohe1

  • 1Jcho Hokkaido Hospital, Clinic of Internal Medicine, Sapporo, Japan

Turkish Journal of Pharmaceutical Sciences
|March 1, 2022
PubMed

Insights

Early treatment with doxycycline, azithromycin, and ivermectin may combat COVID-19-induced ARDS. These drugs, along with corticosteroids, offer anti-inflammatory benefits against cytokine storms and viral replication.

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Immunology

Background:

  • Coronavirus disease-2019 (COVID-19), caused by SARS-CoV-2, emerged as a global health crisis.
  • Limited specific treatments necessitate exploring existing drug classes for therapeutic potential.
  • COVID-19 pathology involves viral replication, cytokine storms, organ damage (ARDS), and thrombosis.

Purpose of the Study:

  • To evaluate the potential of tetracyclines, macrolide antibiotics, and ivermectin (IVM) as COVID-19 treatments.
  • To explore the anti-inflammatory and immunomodulatory properties of these agents in the context of COVID-19.
  • To assess the early treatment strategy combining these drugs with corticosteroids for COVID-19-induced ARDS.

Main Methods:

  • Review of existing literature on the anti-SARS-CoV-2 activities of selected drugs.
  • Analysis of the anti-inflammatory and immunomodulatory mechanisms of tetracyclines, macrolides, and IVM.
  • Consideration of the pathobiology of COVID-19, including viral replication and cytokine storm.

Main Results:

  • Tetracyclines, macrolide antibiotics, and IVM demonstrate anti-SARS-CoV-2 activity.
  • These agents possess significant anti-inflammatory and immunomodulatory effects, reducing cytokine production.
  • Early intervention with doxycycline, azithromycin, IVM, and corticosteroids is proposed.

Conclusions:

  • Doxycycline, azithromycin, and IVM show promise for COVID-19 treatment regimens.
  • The anti-inflammatory and immunomodulatory effects are crucial for mitigating COVID-19 complications.
  • Early combination therapy with these drugs and corticosteroids may be a promising strategy against COVID-19-induced ARDS.

Keywords:
COVID-19azithromycincorticosteroiddoxycyclineivermectin

More Related Videos

An Educational Video Demonstration of How to Prone a Critically Ill Intubated Patient07:16

An Educational Video Demonstration of How to Prone a Critically Ill Intubated Patient

Published on: November 30, 2022

3.6K
Experimental Model to Evaluate Resolution of Pneumonia09:49

Experimental Model to Evaluate Resolution of Pneumonia

Published on: February 17, 2023

1.5K

Related Concept Videos

Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
224
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
479
Acute Respiratory Failure-III01:30

Acute Respiratory Failure-III

Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
370
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
417
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
337
Acute Respiratory Failure-I01:21

Acute Respiratory Failure-I

Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
378